A Phase 1/2a Study to Determine the Dose Response Pharmacokinetics of TSX-011 (Testosterone Undecanoate) in Hypogonadal Males

Trial Profile

A Phase 1/2a Study to Determine the Dose Response Pharmacokinetics of TSX-011 (Testosterone Undecanoate) in Hypogonadal Males

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 29 May 2018

At a glance

  • Drugs Testosterone (Primary)
  • Indications Hypogonadism
  • Focus Pharmacokinetics
  • Sponsors TesoRx
  • Most Recent Events

    • 21 May 2018 Status changed from recruiting to active, no longer recruiting.
    • 30 Nov 2017 According to a TesoRx Pharma media release, enrollment will include at least 10 evaluable native Japanese subjects intended to contribute towards TSX-011 regulatory approval efforts in Japan. Top-line results from this trial are expected in the second half of 2018.
    • 20 Nov 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top